It's How Medicine Should Be®


French German Italian Portuguese Russian

Hemophilia A or B Treatment Study

Clinical Trial Title: 
A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIa (MOD-5014) in adult men with hemophilia A or B, with or without inhibitors.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Lisa Boggio, MD
Clinical Trial Protocol Description: 

This study will consist of 3 time periods: a screening period of up to 28 days, 1 day of drug administration and 29 days of follow-up.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have moderate to severe hemophilia A or B.
  • Are male at least 18 yeras of age.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Lisa Boggio, MD